Biotech Startups

Sable Therapeutics is a biotechnology company that develops beauty and wellness brands built on proprietary scientific discoveries, operating as a house of brands rather than a single product. It applies biotech research, such as a patent-pending dendrimer ingredient, to consumer body care and works with retailers, medical channels, and established brands.

1 investor

Saccharo is a biotech company developing antibody-drug conjugates and other therapeutics targeting dPSA (de-N-acetyl-polysialic acid), a tumor-specific glycan re-expressed on cancer cells, for the treatment of solid tumors and hematologic cancers. Its lead candidate, SAC-253, is a first-in-class ADC with potential broad oncology application, and it also develops diagnostic screening applications.

1 investor

SACRA Therapeutics is a drug discovery company developing therapeutics that target the RNA epitranscriptome, with a focus on oncology. It combines expertise in drug discovery, clinical oncology, and epitranscriptomics to pursue a novel therapeutic approach for patients.

1 investor

Safetest develops, produces, and sells rapid lateral-flow diagnostic test kits for detecting human diseases through isolation of specific antigens, and offers R&D, antigen/antibody conjugation services, training, and technical support. It positions itself as a Brazilian company making fully domestically produced rapid diagnostic tests for researchers, companies, and healthcare applications.

1 investor

Safi Biotherapeutics manufactures adult stem-cell derived human red blood cells (mRBCs) as a cell therapy blood transfusion product, aiming to produce them at industrial scale for civilian and military transfusion needs. Its work targets both chronic transfusion indications, such as sickle cell disease, and acute settings including hospitals and battlefields.

1 investor

Sahlgrenska Science Park is an accelerator and innovation hub that supports life science and health technology companies, located at the Sahlgrenska medical campus in Gothenburg, Sweden. It facilitates collaboration between researchers, clinicians, entrepreneurs, and industry partners to develop and scale healthcare innovations.

1 investor

SAI Med is a healthcare company that aims to improve global healthcare through insights and data-driven solutions. The company operates with experienced leadership teams serving industry and community healthcare needs.

1 investor

PSS Solutions is an independent consulting and advisory group focused on intellectual property, helping organizations improve and manage their IP operations. It combines expertise, strategic advice, and technology to support change management and operational performance.

1 investor

Sama Therapeutics develops iMAGiNE, an AI/ML biomarker platform for precision neuropsychiatry that predicts treatment response across psychiatric and neurological disorders. It serves pharmaceutical and clinical trial developers, care providers, and individuals tracking brain health, operating as software-as-a-medical-device in the neurotechnology and digital health space.

1 investor

Sameric Bio in-licenses multifunctional protein-based biologics (bispecifics, engagers, degraders, enzyme-linked proteins) from academic researchers and develops them from in-vivo/ex-vivo proof of concept to clinical proof of concept. It combines AI-native protein engineering, systems-pharmacology modeling, and a BSL-2 lab to advance drug candidates in high unmet-need indications.

1 investor

SampleFacts develops microsampling devices for simplified blood cell and plasma collection, targeting researchers, clinical study professionals, and healthcare providers. The company builds on university research to enable easier, faster, and more reliable blood sampling for research, clinical studies, and diagnostics.

1 investor

Biopharmaceutical company developing first-in-class therapeutics for rare genetic and neurodegenerative diseases with a focus on autophagy enhancement.

1 investor

Sanavia discovers novel cancer-specific epitopes using proprietary immunization technology and AI to enable more effective antibody therapies for oncology. The company develops epitope discovery platforms and antibody drug candidates targeting multiple cancer types to expand treatment options for patients.

1 investor

SanBio develops regenerative cell-based medicines for patients with neurological conditions, with its lead product SB623 used for chronic motor paralysis following traumatic brain injury. Its approved product is marketed in Japan as an intracerebral implant injection.

1 investor

Sancilio & Company provides guidance and regulatory support to early-stage biopharmaceutical entrepreneurs on compliance, manufacturing, and funding strategy. Through its subsidiary Clearway Global, the firm offers a network of FDA-regulated services including drug manufacturing, formulation development, clinical trials, and regulatory submissions.

1 investor

Sanfer is a pharmaceutical company that develops and markets prescription medicines, over-the-counter products, and animal health products across different therapeutic areas. It operates manufacturing facilities in Mexico and Latin America and provides medical content to prescribers through its Sanfer Conecta app.

1 investor

Sanford Burnham Prebys is a nonprofit biomedical research institute that conducts basic and translational research across cancer, cardiovascular/muscular, neurologic, and metabolic/liver diseases, supported by centers for therapeutics discovery and data science/AI. It also operates a graduate school and post-doctoral training programs and offers technology licensing and partnership opportunities to translate discoveries into treatments.

1 investor

SaniSure develops Mixed4Sure, a single-use mixing platform for small-volume biopharmaceutical processing that handles volumes from 50 mL to 20 L with reduced shear forces and lower capital costs than traditional stainless-steel systems.

1 investor

Sanmai is developing a clinical ultrasound device that uses low-intensity transcranial ultrasound to deliver brain therapeutics. The company, structured as a public benefit corporation, is currently running trials and targets research clinics in the neurotherapeutics field.

1 investor

Sanmirna Therapeutics develops microRNA-targeted therapeutics for cancer treatment, with its lead candidate Miristen™ currently in Phase I clinical trials for acute myeloid leukemia. The company leverages microRNA discovery to create novel oncology treatments.

1 investor

Sanos provides clinical trial management services for pharmaceutical sponsors across multiple therapeutic areas, offering end-to-end capabilities from protocol development through regulatory approval. The company operates as a strategic partner for drug development, managing patient recruitment, data integrity, and operational execution with fixed budgets and timelines.

1 investor

SANSHO Co., Ltd. is a Japanese drug-development company creating pharmaceuticals based on cyclic phosphatidic acid (cPA), including 2-carba-cyclic phosphatidic acid candidates in clinical trials for knee osteoarthritis and pulmonary fibrosis. The company conducts research and development to bring these medicines to clinical use.

1 investor

Santero is a Belgium-based biotech company developing antibacterial drugs, including an RSH inhibitor programme targeting Pseudomonas aeruginosa and multidrug-resistant pathogens. It runs drug discovery and preclinical development spanning computational chemistry, medicinal chemistry, and screening toward clinical development.

1 investor

Saol Therapeutics is a clinical-stage pharmaceutical company focused on developing therapies for CNS disorders, pain conditions, and orphan diseases. The company recently divested its commercial assets to concentrate on advancing its pipeline of late-stage clinical programs.

1 investor